Exclusive: Volpi Capital attracts €428m for third fund
The vehicle aims to complete nine to 10 deals in total, partner Crevan O'Grady tells Real Deals
Latest News
British Emerging Manager Institute launches this week
Real Deals speaks exclusively with founder Ed Stubbings to understand the ambitions of the firm
Investindustrial to buy majority stake in Piovan, seek delisting
Piovan has been listed on the Milan stock exchange since 2018
Value4Capital holds first close for sophomore fund above target
The €110m in commitments surpasses the GP's €100m target and is already 20% larger than its Fund I
MidEuropa acquires pharma contract organisation Famar
The deal marks an exit for existing shareholders ECM Partners and Metric Capital Partners
Ardian acquires pharmaceutical and biotech business Masco Group from RSBG SE
Masco Group’s current management team and the Borella family will reinvest alongside Ardian
Consortium including CapMan Growth make offer for listed Innofactor shares
Being listed has 'limited growth and profit potential' says Innofactor boss, who stands to increase his own stake
Insights
Future 40 2024: Peak performers
This year’s Future 40 Mid-Market Investment Leaders list, in association with Finatal, recognises those dealmakers who have navigated another 12 months of challenging conditions to deliver successful outcomes
Roundtable: Midmarket debt open for business
In a Real Deals roundtable discussion, lenders and advisers shared their thoughts on how signs of cooling inflation and peak interest rates are shaping the midmarket debt landscape, and what this means for the months ahead
Second act: Unlocking the true potential of continuation funds
Amid a sluggish exit environment, continuation funds have emerged as a true alternative to traditional M&A processes. Greg Gille rounds up the key takeaways from our recent breakfast briefing
State of the market: Private equity’s big boardroom topics
For nearly two years private equity has been wrestling with a fractured market. As the industry reaches the halfway mark of 2024, it’s clear that waiting out the downturn for a return of better conditions is not an option, as Shivani Khandekar finds out
Market surges as GPs light the blue touch paper in June – Real Deals Database
Later-stage PE investors capped off an active second quarter with an especially bullish June, announcing a raft of larger deals that will eat into the reserves of dry powder and provide much-needed liquidity, as Julian Longhurst reports
Nordic environmental sustainability here to stay
With ESG investing encountering increasingly noisy resistance in some parts of the world, Xhulio Ismalaj explores how the Nordic countries’ commitment to sustainability remains deeply embedded
Deals
Investindustrial to buy majority stake in Piovan, seek delisting
Piovan has been listed on the Milan stock exchange since 2018
MidEuropa acquires pharma contract organisation Famar
The deal marks an exit for existing shareholders ECM Partners and Metric Capital Partners
Ardian acquires pharmaceutical and biotech business Masco Group from RSBG SE
Masco Group’s current management team and the Borella family will reinvest alongside Ardian
Consortium including CapMan Growth make offer for listed Innofactor shares
Being listed has 'limited growth and profit potential' says Innofactor boss, who stands to increase his own stake
Equistone seals twin trade sales
European midmarket GP has sold Heras to Garda Group and Otto LSE to Spie Group
BaltCap finalises Fitekin and ONEA acquisitions
The investment was made from BaltCap Private Equity Fund III
Funds
Value4Capital holds first close for sophomore fund above target
The €110m in commitments surpasses the GP's €100m target and is already 20% larger than its Fund I
Exclusive: Volpi Capital attracts €428m for third fund
The vehicle aims to complete nine to 10 deals in total, partner Crevan O'Grady tells Real Deals
Nextalia venture fund closes on €150m hard-cap
Italian investor completed fundraising after six months in market
Astorg raises €1.4bn continuation vehicle
Single-asset Normec continuation fund was capitalised by lead investors CVC Secondary Partners, Pantheon, Lexington Partners and Eurazeo
Biovance Capital I holds first closing on €51m
Key investors in Biovance Capital I – which has a target size of €60m – include the EIF, Banco Português de Fomento and the European Commission
Kembara Fund I secures €350m commitment from EIF
Alma Mundi Ventures aims to make investments in European deeptech and climate companies at the growth stage